Tens of thousands of Kaiser Permanente workers in California and Hawaii have gone on strike, demanding safer staffing levels ...

Insurers are cutting coverage for costly GLP-1 weight loss drugs, sparking backlash from advocates who say they're vital for ...

Experts warn that the Trump administration’s new $100,000 fee for H-1B visa applications could worsen healthcare’s workforce ...

The government shutdown is drawing backlash from healthcare leaders over its potential to disrupt ACA subsidies, Medicare ...

Novo Nordisk is acquiring Akero Therapeutics for drug candidate efruxifermin, which executive say could be first and best in ...

Seven months ago, independent clinical trial observers peeked at interim data for Praxis Precision Medicines’ essential tremor drug and recommended stopping the Phase 3 studies. Praxis kept going. On ...

Amazon is no stranger to experimenting in healthcare even if it means acknowledging failure. Its latest bold venture? In-office pharmacy kiosks at One Medical offices so patients can access their ...

It goes without saying that this past year has been anything but easy for UnitedHealth Group. As one of the biggest healthcare companies in the U.S., it has long been a reliable stock to invest in.

Novo Nordisk is paying $240 million up front for global rights to zaltenibart, an Omeros drug that blocks the MASP-3 protein to treat diseases caused by excessive activity of the complement system.

Stephanie Baum is the Director of Special Projects for MedCityNews. She graduated from Franklin & Marshall College in Pennsylvania and has worked across radio, print and video. She's worked for Dow ...

Katie Adams is a senior reporter for MedCity News covering providers and healthcare technology. Previously, she worked as a healthcare technology editor at Becker’s Hospital Review. Her journalism ...